A Platform Study for solId orgaN CancERs

NCT05650125 | Recruiting

• 1 other identifier: 174008
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Generating bespoke biosampling protocols for individual tumour specific translational projects is onerous, cumbersome and inefficient. This study aims to provide a broad platform to maximise the unique access to biopsy and resected tumour specimens available from cancer patients to provide a high-quality and efficient source of biosamples for specific translational projects. Access to historical FFPE samples and clinical data, as well as prospective fresh tissue samples, will allow interrogation of the underlying biology of these cancers. Matched pseudoanonymised clinical and radiological data will allow the development of rich high-yield datasets.

Conditions

Cancer; Surgery

Keywords

Surgery; Cancer; Translational; Biosample; Cohort

Outcome Measures

Primary Outcomes (1)

• Biosample procurement

  Patient biosamples delivered via platform

  4 years

Study Arms (1)

Patients with solid organ cancer

Prospective biosampling of blood/tissue

Other: Biosampling

Interventions

Biosampling OTHER

Biosampling of blood/tumour/adjacent normal tissue

Patients with solid organ cancer

Eligibility Criteria

• Age: 16 Years - 100 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with a solid organ malignancy requiring surgery or biopsy as part of their routine clinical care as decided by the specialist MDT.

You may qualify if:

• Biopsy or surgical resection as standard of care

You may not qualify if:

• Refusal or inability to consent, paediatric patients

Sponsors & Collaborators

• University of Liverpool: lead
• Countess of Chester NHS Foundation Trust: collaborator
• Liverpool University Hospitals NHS Foundation Trust: collaborator
• Clatterbridge Centre for Oncology: collaborator
• Liverpool Heart and Chest Hospital NHS Foundation Trust: collaborator
• Liverpool Womens Hospital: collaborator

Study Sites (1)

University of Liverpool

Liverpool, L69 3GB, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Primary \& metastatic tumour (biopsy/resection) - FFPE, fresh tissue, whole blood

MeSH Terms

Conditions

Neoplasms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2022
• First Posted: December 14, 2022
• Study Start: January 1, 2022
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): January 1, 2030
• Last Updated: August 1, 2025

Record last verified: 2025-07

Locations

GB (1)